Advisors Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.97M Sell
41,171
-4,900
-11% -$211K 0.03% 607
2026
Q1
$1.69M Buy
46,071
+11,816
+34% +$560K 0.03% 653
2025
Q4
$1.74M Sell
34,255
-8,880
-21% -$454K 0.03% 638
2025
Q3
$2.39M Sell
43,135
-13,960
-24% -$817K 0.04% 536
2025
Q2
$3.94M Sell
57,095
-20,804
-27% -$1.42M 0.07% 378
2025
Q1
$5.41M Sell
77,899
-1,340
-2% -$111K 0.1% 255
2024
Q4
$6.82M Sell
79,239
-17,497
-18% -$1.89M 0.13% 184
2024
Q3
$11.5M Buy
96,736
+13,668
+16% +$1.82M 0.21% 105
2024
Q2
$11.9M Buy
83,068
+14,968
+22% +$1.98M 0.23% 81
2024
Q1
$8.74M Buy
68,100
+17,035
+33% +$2.03M 0.17% 141
2023
Q4
$5.28M Buy
51,065
+5,440
+12% +$538K 0.11% 231
2023
Q3
$4.15M Buy
45,625
+8,061
+21% +$710K 0.09% 284
2023
Q2
$3.04M Buy
37,564
+6,854
+22% +$560K 0.06% 379
2023
Q1
$2.44M Buy
30,710
+824
+3% +$58.4K 0.05% 459
2022
Q4
$2.02M Buy
29,886
+10,694
+56% +$627K 0.04% 495
2022
Q3
$956K Buy
19,192
+540
+3% +$28.9K 0.02% 743
2022
Q2
$1.04M Buy
18,652
+5,632
+43% +$313K 0.02% 746
2022
Q1
$723K Sell
13,020
-2,616
-17% -$134K 0.01% 896
2021
Q4
$876K Sell
15,636
-1,160
-7% -$62.8K 0.01% 856
2021
Q3
$806K Buy
16,796
+1,120
+7% +$54.1K 0.01% 887
2021
Q2
$657K Buy
15,676
+2,310
+17% +$89.5K 0.01% 942
2021
Q1
$451K Buy
13,366
+3,082
+30% +$110K 0.01% 1038
2020
Q4
$359K Sell
10,284
-1,800
-15% -$62.2K 0.01% 1069
2020
Q3
$419K Buy
12,084
+646
+6% +$21.5K 0.01% 967
2020
Q2
$374K Sell
11,438
-2,042
-15% -$65.2K 0.01% 993
2020
Q1
$406K Sell
13,480
-11,604
-46% -$346K 0.01% 901
2019
Q4
$726K Sell
25,084
-3,358
-12% -$93K 0.01% 859
2019
Q3
$735K Sell
28,442
-12,990
-31% -$328K 0.01% 858
2019
Q2
$1.06M Buy
41,432
+1,806
+5% +$44.6K 0.02% 760
2019
Q1
$1.04M Buy
39,626
+2,804
+8% +$68.9K 0.02% 775
2018
Q4
$848K Buy
36,822
+3,538
+11% +$78.6K 0.02% 818
2018
Q3
$785K Sell
33,284
-1,148
-3% -$28K 0.01% 924
2018
Q2
$794K Buy
34,432
+14,470
+72% +$344K 0.01% 917
2018
Q1
$514K Buy
19,962
+398
+2% +$10.4K 0.01% 1048
2017
Q4
$525K Buy
19,564
+5,202
+36% +$132K 0.01% 1065
2017
Q3
$346K Sell
14,362
-7,688
-35% -$174K 0.01% 1150
2017
Q2
$473K Sell
22,050
-3,666
-14% -$74K 0.01% 1115
2017
Q1
$441K Sell
25,716
-53,722
-68% -$935K 0.01% 1144
2016
Q4
$1.42M Sell
79,438
-10,686
-12% -$194K 0.02% 758
2016
Q3
$1.87M Sell
90,124
-45,812
-34% -$1.14M 0.03% 640
2016
Q2
$3.65M Sell
135,936
-14,064
-9% -$386K 0.06% 456
2016
Q1
$4.06M Sell
150,000
-42,226
-22% -$1.13M 0.07% 418
2015
Q4
$5.58M Sell
192,226
-6,696
-3% -$185K 0.09% 324
2015
Q3
$5.39M Buy
198,922
+5,168
+3% +$146K 0.09% 322
2015
Q2
$5.3M Buy
193,754
+21,132
+12% +$594K 0.07% 369
2015
Q1
$4.61M Buy
172,622
+22,862
+15% +$526K 0.06% 402
2014
Q4
$3.17M Buy
149,760
+14,662
+11% +$328K 0.04% 488
2014
Q3
$3.22M Buy
135,098
+10,966
+9% +$252K 0.04% 454
2014
Q2
$2.87M Buy
124,132
+15,646
+14% +$345K 0.04% 482
2014
Q1
$2.48M Buy
108,486
+22,346
+26% +$476K 0.04% 498
2013
Q4
$1.59M Buy
86,140
+11,610
+16% +$202K 0.03% 584
2013
Q3
$1.26M Buy
74,530
+4,750
+7% +$79.9K 0.02% 610
2013
Q2
$1.08M Buy
+69,780
New +$1.16M 0.02% 617

Other funds holding NVO

Advisors Asset Management's NVO Position: Q2 2026 in Review

Advisors Asset Management reduced its Novo Nordisk (NVO) stake by 11% in Q2 2026, selling an estimated $211K and leaving 41,171 shares worth $1.97M. The position accounts for 0.03% of the portfolio, ranked #607.

Advisors Asset Management first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.9M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Advisors Asset Management held 41,171 shares of Novo Nordisk worth $1.97M as of Q2 2026.
  • Advisors Asset Management sold 4,900 Novo Nordisk shares in Q2 2026, an estimated $211K.
  • Novo Nordisk made up 0.03% of Advisors Asset Management's portfolio in Q2 2026, its #607 holding.
  • Advisors Asset Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Advisors Asset Management's Novo Nordisk position peaked at $11.9M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.